Metropolis Healthcare Sustains Strong Growth Momentum; Revenue Rises 26% YoY to ₹406 Crore; PAT Surges 63%

Metropolis Healthcare Limited, India’s second-largest and most trusted pathology laboratory chain, announced its unaudited consolidated financial results for the quarter ended December 31, 2026 (Q3FY26). The company reported a 26% YoY increase in revenue, amounting to ₹406 Crore, and a 63% YoY surge in PAT, excluding an exceptional item. Patient and test volumes grew 14% and 13% YoY, respectively, driven by steady demand trends, deeper penetration across Tier Il and Tier lll markets, and a favourable mix shift toward complex and specialised testing. B2C revenues grew 19% YoY and B2B revenues grew ~35% YoY, supported by network expansion, improved service levels, and consistent execution across channels. TruHealth and Specialty portfolios recorded strong growth of ~37% and ~34% YoY, respectively. Revenue per Test (RPT) and Revenue per Patient (RPP) increased 11% and 10% YoY, respectively. North India’s revenue contribution was at 17%, while Tier lll cities registered 16% revenue growth and contributed 24% to overall revenues. The Board approved a 3:1 bonus issue of equity shares.